Biotech | September 08, 2021
Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
The trial will be conducted across 10 sites in India
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Subscribe To Our Newsletter & Stay Updated
